The DOI matches its Crossref record; 96 of the 99 references it cites were found in a registry or an index.
L-asparaginase in the treatment of patients with acute lymphoblastic leukemia
Open accessAbstract
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy that predominantly occurs in children between 2 and 10 years of age. L-asparaginase is an integral component of treatment for patients with ALL and since its introduction into pediatric treatment protocols in the 1960s, survival rates in children have progressively risen to nearly 90%. Outcomes for adolescent and young adult (AYA) patients, aged 15-39 years and diagnosed with ALL, have historically been less favorable. However, recent reports suggest substantially increased survival in AYA patients treated on pediatric-inspired protocols that include a greater cumulative dose of asparaginase. All currently available asparaginases share the same mechanism of action - the deamination and depletion of serum asparagine levels - yet each displays a markedly different pharmacokinetic profile. Pegylated asparaginase derived from the bacterium Escherichia coli is used as first-line therapy; however, up to 30% of patients develop a treatment-limiting hypersensitivity reaction. Patients who experience a hypersensitivity reaction to an E. coli-derived asparaginase can continue treatment with Erwinia chrysanthemi asparaginase. Erwinia asparaginase is immunologically distinct from E. coli-derived asparaginases and exhibits no cross-reactivity. Studies have shown that with adequate dosing, therapeutic levels of Erwinia asparaginase activity can be achieved, and patients switched to Erwinia asparaginase due to hypersensitivity can obtain outcomes similar to patients who do not experience a hypersensitivity reaction. Therapeutic drug monitoring may be required to ensure that therapeutic levels of asparaginase activity are maintained.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“L-asparaginase has been found to be effective in the treatment of ALL and is included in standard chemotherapy regimens for this disease (Table 1)(Egler et al., 2016).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Egler et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treatment of Acute Lymphoblastic Leukemia
Pui, C., & Evans, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052603 · Cited by 2,012
Pui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
Hunger, S. P., Lu, X., Devidas, M., Camitta, B. M., Gaynon, P. S., Winick, N. J., Reaman, G. H., & Carroll, W. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.8018 · Cited by 1,177
Silverman, L. B. (2001) · Blood · doi:10.1182/blood.v97.5.1211 · Cited by 869
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
Kantarjian, H. M., O'Brien, S. M., Smith, T. L., Cortes, J. E., Giles, F. J., Beran, M., Pierce, S. A., Huh, Y. O., Andreeff, M., Koller, C. A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.547 · Cited by 796
Armstrong, J. K., Hempel, G., Koling, S., Chan, L. S., Fisher, T., Meiselman, H. J., & Garratty, G. (2007) · Cancer · doi:10.1002/cncr.22739 · Cited by 699
Kantarjian, H. M., Thomas, D. A., O'Brien, S. M., Cortes, J. E., Giles, F. J., Jeha, S., Bueso-Ramos, C., Pierce, S. A., Shan, J., Koller, C. A., et al. (2004) · Cancer · doi:10.1002/cncr.20668 · Cited by 638
Boissel, N., Auclerc, M.-F., Lhéritier, V., Pérel, Y., Thomas, X., Leblanc, T. M., Rousselot, P. H., Cayuela, J., Gabert, J. A., Fegueux, N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.053 · Cited by 606
L‐asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase
Pieters, R., Hunger, S. P., Boos, J., Rizzari, C., Silverman, L., Baruchel, A., Goekbuget, N., Schrappe, M., & Pui, C. (2011) · Cancer · doi:10.1002/cncr.25489 · Cited by 569
Huguet, F., Leguay, T., Raffoux, E., Thomas, X., Beldjord, K., Delabesse, É., Chevallier, P., Buzyn, A., Delannoy, A., Chalandon, Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6916 · Cited by 566
Research works printed but not linked: 6
- [1]Gaynon P Schrappe M Cairo M Perkins S Childhood ALL Hematological Malignancies in Children, Adolescents and Young Adults 2012 Hackensack, NJ World Scientific Publishing Company 197 235
- [2]Howlader N Noone AM Krapcho M Garshell J Neyman N Altekruse SF National Cancer Institute. Section 28: Childhood cancer by site, incidence, survival, and mortality SEER Cancer Statistics Review, 1975-2011 2014 Bethesda, MD National Cancer Institute
- [7]Broome JD Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance J Exp Med 1963 118 99 120 14015821 PMC2137570
- [21]Clarkson B Krakoff I Burchenal J Karnofsky D Golbey R Dowling M Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors Cancer 1970 25 279 305 4905154
- [55]Oettgen HF Stephenson PA Schwartz MK Leeper RD Tallai L Tan CC Toxicity of E. coli L-asparaginase in man Cancer 1970 25 253 78 4905153
- [71]Schwartz MK Lash ED Oettgen HF Tomato FA L-asparaginase activity in plasma and other biological fluids Cancer 1970 25 244 52 4905152
Cited by
Sorted by citations
Targeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971
Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors
Andrejeva, G., & Rathmell, J. C. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.004 · Cited by 374
Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia
Teachey, D. T., & Pui, C. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30031-2 · Cited by 295
Emerging therapies in cancer metabolism
Xiao, Y., Yu, T., Xu, Y., Ding, R., Wang, Y.-P., Jiang, Y., & Shao, Z. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.006 · Cited by 279
Abou‐Alfa, G. K., Qin, S., Ryoo, B., Lu, S., Yen, C.-J., Feng, Y., Lim, H. Y., Izzo, F., Colombo, M., Sarker, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy101 · Cited by 236
Metadata
- Authors
- Egler, R. A., Ahuja, S. P., & Matloub, Y.
- Affiliations
- Rainbow Babies & Children's Hospital (US)
- Corresponding author
- Egler, Rachel A.
- ORCID
- Ahuja, Sanjay P.
- Venue
- Journal of Pharmacology and Pharmacotherapeutics
- Publisher
- SAGE Publications
- Published
- 2016-06
- Volume
- 7
- Issue
- 2
- Pages
- 62-71
- ISSN
- 0976-500X (ISSN-L)
- 0976-5018
- PMC
- PMC4936081
- OpenAlex
- W2471256249
- Cited by
- 334
- References
- 99
- Citations by year
- 2026: 24 · 2025: 28 · 2024: 42 · 2023: 50 · 2022: 36 · 2021: 55 · 2020: 37 · 2019: 26 · 2018: 17 · 2017: 17 · 2016: 1
- FWCI
- 20.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Pharmacology and Pharmacotherapeutics (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- L-asparaginase, acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia, adolescent and young adult leukemia, pegylated asparaginase, hypersensitivity, cross-reactivity, pharmacokinetics, therapeutic drug monitoring, survival outcomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
